Meeting
2022 ASCO Annual Meeting
Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.
Authors
F. Stephen Hodi
Dana-Farber Cancer Institute, Boston, MA
F. Stephen Hodi , Vanna Chiarion -Sileni , Karl D. Lewis , Jean-Jacques Grob , Piotr Rutkowski , Christopher D. Lao , Charles Lance Cowey , Dirk Schadendorf , John Wagstaff , Reinhard Dummer , Paola Queirolo , Michael Smylie , Marcus O. Butler , Andrew Graham Hill , Ivan Marquez-Rodas , John B. A. G. Haanen , Piyush Durani , Peter Wang , Jedd D. Wolchok , James Larkin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04540705
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9522)
DOI
10.1200/JCO.2022.40.16_suppl.9522
Abstract #
9522
Poster Bd #
115
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).
First Author: Dirk Schadendorf
Poster
2022 ASCO Annual Meeting
A phase II study to evaluate the safety and efficacy of IMM-101 in combination with checkpoint inhibitors in patients with advanced melanoma: Final results of the IMM-101-015 trial.
First Author: Alberto Fusi
Poster
2021 ASCO Annual Meeting
Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.
First Author: Celeste Lebbe
Poster
2020 ASCO Virtual Scientific Program
FDG-PET metabolic tumor volume in advanced melanoma treated with ipilimumab and nivolumab (ipi/nivo).
First Author: Amir Iravani